Cargando…

Photoimmunotherapy: A New Paradigm in Solid Tumor Immunotherapy

In recent years, the incidence of cancer has been increasing worldwide. Conventional cancer treatments include surgery, chemotherapy, and radiation, which mostly kill tumor cells at the expense of normal and immune cells. Although immunotherapy is an accurate, rapid, efficient tumor immune treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Zheng, Lv, Xiaolan, Huang, Shigao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9016614/
http://dx.doi.org/10.1177/10732748221088825
_version_ 1784688565265891328
author Peng, Zheng
Lv, Xiaolan
Huang, Shigao
author_facet Peng, Zheng
Lv, Xiaolan
Huang, Shigao
author_sort Peng, Zheng
collection PubMed
description In recent years, the incidence of cancer has been increasing worldwide. Conventional cancer treatments include surgery, chemotherapy, and radiation, which mostly kill tumor cells at the expense of normal and immune cells. Although immunotherapy is an accurate, rapid, efficient tumor immune treatment, it causes serious adverse reactions, such as cytokine release syndrome (CRS) and neurotoxicity. Therefore, there is an urgent need to develop an effective and nontoxic procedure for immunotherapy. The clinical combination of phototherapy and immunoadjuvant therapy can induce immunogenic cell death and enhance antigen presentation synergy. It also causes a systemic antitumor immune response to manage residual tumors and distant metastases. Photoimmunotherapy (PIT) is a tumor treatment combining phototherapy with immunotherapy based on injecting a conjugate photosensitizer (IR700) and a monoclonal antibody (mAb) to target an expressed antigen on the tumor surface. This combination can enhance the immune response ability, thus having a good effect on the treatment of residual tumor and metastatic cancer. In this review, we summarize the recent progress in photoimmunotherapy, including photoimmunoconjugate (PIC), the activation mechanism of immunogenic cell death (ICD), the combination therapy model, opportunities and prospects. Specifically, we aim to provide a promising clinical therapy for solid tumor clinical transformation.
format Online
Article
Text
id pubmed-9016614
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-90166142022-04-20 Photoimmunotherapy: A New Paradigm in Solid Tumor Immunotherapy Peng, Zheng Lv, Xiaolan Huang, Shigao Cancer Control Precise medicine in cancer control: from immunotherapy to artificial intelligence - Review In recent years, the incidence of cancer has been increasing worldwide. Conventional cancer treatments include surgery, chemotherapy, and radiation, which mostly kill tumor cells at the expense of normal and immune cells. Although immunotherapy is an accurate, rapid, efficient tumor immune treatment, it causes serious adverse reactions, such as cytokine release syndrome (CRS) and neurotoxicity. Therefore, there is an urgent need to develop an effective and nontoxic procedure for immunotherapy. The clinical combination of phototherapy and immunoadjuvant therapy can induce immunogenic cell death and enhance antigen presentation synergy. It also causes a systemic antitumor immune response to manage residual tumors and distant metastases. Photoimmunotherapy (PIT) is a tumor treatment combining phototherapy with immunotherapy based on injecting a conjugate photosensitizer (IR700) and a monoclonal antibody (mAb) to target an expressed antigen on the tumor surface. This combination can enhance the immune response ability, thus having a good effect on the treatment of residual tumor and metastatic cancer. In this review, we summarize the recent progress in photoimmunotherapy, including photoimmunoconjugate (PIC), the activation mechanism of immunogenic cell death (ICD), the combination therapy model, opportunities and prospects. Specifically, we aim to provide a promising clinical therapy for solid tumor clinical transformation. SAGE Publications 2022-04-13 /pmc/articles/PMC9016614/ http://dx.doi.org/10.1177/10732748221088825 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Precise medicine in cancer control: from immunotherapy to artificial intelligence - Review
Peng, Zheng
Lv, Xiaolan
Huang, Shigao
Photoimmunotherapy: A New Paradigm in Solid Tumor Immunotherapy
title Photoimmunotherapy: A New Paradigm in Solid Tumor Immunotherapy
title_full Photoimmunotherapy: A New Paradigm in Solid Tumor Immunotherapy
title_fullStr Photoimmunotherapy: A New Paradigm in Solid Tumor Immunotherapy
title_full_unstemmed Photoimmunotherapy: A New Paradigm in Solid Tumor Immunotherapy
title_short Photoimmunotherapy: A New Paradigm in Solid Tumor Immunotherapy
title_sort photoimmunotherapy: a new paradigm in solid tumor immunotherapy
topic Precise medicine in cancer control: from immunotherapy to artificial intelligence - Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9016614/
http://dx.doi.org/10.1177/10732748221088825
work_keys_str_mv AT pengzheng photoimmunotherapyanewparadigminsolidtumorimmunotherapy
AT lvxiaolan photoimmunotherapyanewparadigminsolidtumorimmunotherapy
AT huangshigao photoimmunotherapyanewparadigminsolidtumorimmunotherapy